Does marijuana rescheduling in the US make Canopy Growth a good buy in 2026?
The company has banked its hopes heavily on the prospects for marijuana legalization in the U.S., and it’s paid a steep price in recent years for doing so. Buying a stock based on the expectation that …
Legal Marijuana Access Faces An Existential Threat In 2026, And We Must Fight Back (Op-Ed)
These initiatives represent the first-ever large-scale coordinated attack on adult-use markets… This is not a drill. It is the moment to come together to defeat the prohibitionists.” By Adam Smith, …
Bemidji Planning Commission to review First City Cannabis, Julie Canty responds
On Dec. 18, the Bemidji Planning Commission motioned to table Julie Canty’s First City Cannabis project to allow legal counsel time to prepare findings to deny the project. It will be considered again …
CT announces $416K settlement with cannabis business in premature ‘gun-jumping’ in merger
The company, Crisp Cannabis, has three establishments in Bridgeport, East Hartford and Cromwell, the release said. The company that is seeking to acquire the businesses, Mohave CT LLC, also was …
Safer bus lanes and cannabis equity are part of packed City Council agenda
Santa Monica City Council will consider changes to cannabis equity requirements and approve $1.6M for automated bike lane enforcement and real-time bus tracking.
CBD Stocks Creating Opportunities – Established (BCCI), (STG), (WEED), (ACRGF), (RLTR), (CBMJ), and Newcomer (VAPR) Lead the Charge
You would have to be living in isolation to have not picked up on the hottest marijuana derivative consumable and therapeutic center isolate CBD. CBD “Cannabidiol” is the non-psychoactive full spectrum derivative of the hemp and marijuana plant largely credited for the majority of the medical beneficial attributes associated with marijuana.
While Investors Chase Monday’s Tilray, Canopy And Aurora Rally, A Potential Federal Shift Could Redefine Cannabis Growth Fundamentals
Shares of major cannabis companies are trading higher Monday morning. The stocks are soaring following a WSJ report that President Trump is considering reclassifying marijuana as a less dangerous drug …
Cannabis Stocks Rally as Trump Mulls Marijuana Reclassification
Shares of Canopy Growth Corp (NASDAQ:CGC) jumped 19.2% on Monday amid reports that President Donald Trump is considering lowering marijuana’s federal classification, a move that could reshape the …
Cannabis stocks rally after Trump says he is weighing drug reclassification
Cannabis stocks rallied after President Donald Trump said he might reclassify marijuana as having a lower danger level. Such a move would be “a game changer” for the industry, one money manager said.
Cannabis stocks rally as Trump reportedly weighs rescheduling
Canadian cannabis stocks surge as Trump considers rescheduling marijuana as a less dangerous drug under the Controlled Substances Act. Read more here.
CBD of Denver Reflects on 2024 and Announces Withdrawal from German Market Amid Political Uncertainty
Denver, Colorado–(Newsfile Corp. – February 25, 2025) – CBD of Denver, Inc. (OTC Pink: CBDD) today announced that it is shifting its focus and will no longer seek to provide services to the …
The best CBD tincture
Which CBD tincture is best? CBD tinctures contain the active ingredient cannabidiol, which is one of more than 100 cannabinoids found in the hemp, or cannabis, plant. CBD has been found to relieve …
FUSION CBD PRODUCTS CAN HELP YOU STICK TO YOUR NEW YEAR’S RESOLUTIONS
MIAMI, Feb. 21, 2025 /PRNewswire/ — If you, like nearly 80% of Americans, are determined to lead a healthier, more active lifestyle in 2025, maybe it’s time to look at some Fusion CBD Products …
CBD Is About to Get Big (Again)
After a blistering rise and subsequent fall in the beauty industry, the buzzy ingredient is seeking its second act.
JPMorgan cuts CBD stock rating to Underweight on leverage concerns
On Tuesday, JPMorgan issued a downgrade for Cia Brasileira de Distribuicao (PCAR3:BZ) (NYSE:CBD), moving its stock rating from Neutral to Underweight. The change in rating by JPMorgan analyst …
Recent Comments